Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.
Boon H, Bosselaar M, Praet SF, Blaak EE, Saris WH, Wagenmakers AJ, McGee SL, Tack CJ, Smits P, Hargreaves M, van Loon LJ.
Diabetologia. 2008 Oct;51(10):1893-900. Epub 2008 Aug 16.PMID: 18709353 [PubMed - indexed for MEDLINE]Related articles